You are here: Industry Insights > NF1

News List

Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial europeanpharmaceuticalreview
January 18, 2021
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.
Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1 americanpharmaceuticalreview
July 09, 2020
AstraZeneca announced selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease.
AstraZeneca, Merck secure FDA nod for Koselugo to treat paediatric patients with NF1 genetic disorder pharmaceutical-business-review
April 14, 2020
AstraZeneca and Merck have secured approval from the US Food and Drug Administration (FDA) for Koselugo (selumetinib) .
FDA approves AstraZeneca’s Koselugo to treat rare genetic disorder pharmaceutical-technology
April 14, 2020
AstraZeneca and MSD (Merck) have received the US Food and Drug Administration (FDA) approval for Koselugo (selumetinib) to treat a rare genetic condition called neurofibromatosis type 1 (NF1).
Certain brain tumours could respond to immunotherapy pharmaphorum
December 12, 2018
Some brain tumours may respond to immunotherapy after all, according to a new study.So far, brain tumours have been resistant to immunotherapy drugs because.....